SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-013914
Filing Date
2023-08-08
Accepted
2023-08-08 16:02:33
Documents
68
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20230630x10q.htm   iXBRL 10-Q 1881512
2 EX-10.2 crvs-20230630xex10d2.htm EX-10.2 28143
3 EX-31.1 crvs-20230630xex31d1.htm EX-31.1 11895
4 EX-31.2 crvs-20230630xex31d2.htm EX-31.2 11833
5 EX-32.1 crvs-20230630xex32d1.htm EX-32.1 11807
6 GRAPHIC crvs-20230630x10q006.jpg GRAPHIC 77169
  Complete submission text file 0001558370-23-013914.txt   7024217

Data Files

Seq Description Document Type Size
7 EX-101.SCH crvs-20230630.xsd EX-101.SCH 41768
8 EX-101.CAL crvs-20230630_cal.xml EX-101.CAL 48024
9 EX-101.DEF crvs-20230630_def.xml EX-101.DEF 152347
10 EX-101.LAB crvs-20230630_lab.xml EX-101.LAB 367441
11 EX-101.PRE crvs-20230630_pre.xml EX-101.PRE 276524
62 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20230630x10q_htm.xml XML 1136087
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 231151091
SIC: 2834 Pharmaceutical Preparations